Rahul Dhanda, Syntis Bio CEO
June 11, 2024 07:25 AM EDTUpdated 07:54 AM
Financing

New obe­si­ty biotech Syn­tis Bio launch­es with ear­ly-stage al­ter­na­tive to GLP-1s

Katherine Lewin

News Reporter

Syn­tis Bio is join­ing a grow­ing group of small­er com­pa­nies that are mov­ing in­to the obe­si­ty treat­ment space — but not with a GLP-1.

In­stead, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times